StockData
REGENXBIO Inc. logo

REGENXBIO Inc. (RGNX) stock

RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.26+0.02 (+0.28%)

Close on Nov 18, 2026Market cap $479.26MP/E –Yield –

Regenxbio price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Regenxbio's price to book ratio was 6.4× on Nov 11, 2026, against 4.2× a year earlier. Over the last 5 years it ranged from 1.2× to 29.3×, with a median of 1.8×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.4×+1.9
2025Dec 31, 20254.5×+3.2
2024Dec 31, 20241.3×−0.9
2023Dec 29, 20232.2×+0.4
2022Dec 30, 20221.7×−1.3
2021Dec 31, 20213.0×−1.1
2020Dec 31, 20204.1×+0.9
2019Dec 31, 20193.2×+0.2
2018Dec 31, 20183.0×−2.3
2017Dec 29, 20175.3×+2.6
2016Dec 30, 20162.7×+0.8
2015Dec 31, 20152.0×–

More Regenxbio figures

See a number that looks wrong?